In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the departments of ophthalmology and biomedical engineering, to play a pivotal ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
In the spring of 2024, the US Food and Drug Administration (FDA) approved fidanacogene elaparvovec (Beqvez), only the second gene therapy product for hemophilia B. Just a few months later, the Pfizer ...
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
DURHAM, N.C. (WTVD) -- Duke Eye Center has become the first academic medical center in the country to implant a new ...
The trial was small — just 12 children were treated in one or both ears — but it offers important lessons for researchers about the potential of Regeneron’s gene therapy.
The Chosun Ilbo on MSN
FDA Speeds Up Custom Gene Therapy Approvals With Existing Data
Last May, people were thrilled to learn that a 7-month-old baby who became the first in the world to receive a personalized ...
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback